Report and recommendations of the workshop of the European centre for the validation of alternative methods for drug-induced cardiotoxicity

Cardiovascular Toxicology

Volumn 9, Issue 3, 2009, Pages 107-125

  Stummann, Tina C ^a   Beilmann, Mario ^b   Duker, Göran ^c   Dumotier, Berengere ^d   Fredriksson, J Magnus ^e   Jones, Robin L ^f   Hasiwa, Marina ^a   Kang, Y James ^g   Mandenius, Carl Fredrik ^e   Meyer, Thomas ^h   Minotti, Giorgio ⁱ   Valentin, Y Jean Pierre ^j   Zünkler, Bernd J ^k   Bremer, Susanne ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c ASTRAZENECA R AND D   (Sweden)

^d NOVARTIS PHARMA AG   (Switzerland)

^e LINKÖPING UNIVERSITY   (Sweden)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g University of Louisville School of Medicine   (United States)

^h MULTI CHANNEL SYSTEMS MCS GMBH   (Germany)

ⁱ UNIVERSITY OF CHIETI   (Italy)

^j ASTRAZENECA   (United Kingdom)

^k FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

more..

Author keywords

Alternative tests; Arrhythmias; Cardiotoxicity; Contractility toxicity; Drugs; Ischaemia toxicity; Secondary cardiotoxicity; Valve toxicity

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENERGIC RECEPTOR; AMIODARONE; CABERGOLINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CARVEDILOL; DEXFENFLURAMINE; EBASTINE; ERGOTAMINE; FENFLURAMINE; FLECAINIDE; ION CHANNEL; IVABRADINE; LIDOCAINE; MUSCARINIC RECEPTOR; PERGOLIDE; RYANODINE RECEPTOR 2; SALBUTAMOL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SEROTONIN AGONIST; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL BLOCKING AGENT; SODIUM PROTON EXCHANGE PROTEIN; TAMOXIFEN; UNINDEXED DRUG; VERAPAMIL; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL; CARDIOTOXIN;

ANGINA PECTORIS; ANIMAL TESTING ALTERNATIVE; AUTOMATION; BINDING ASSAY; BRADYCARDIA; CALCIUM CELL LEVEL; CARDIOTOXICITY; CLINICAL FEATURE; COMPUTER MODEL; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; DISEASE MODEL; DRUG LEGISLATION; DRUG SAFETY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEART REPOLARIZATION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ION CURRENT; ISOLATED HEART; MICROELECTRODE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN FUNCTION; QT PROLONGATION; RISK ASSESSMENT; TISSUE PREPARATION; TOXICITY TESTING; VALIDATION STUDY; VALVULAR HEART DISEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; EDUCATION; EUROPE; EXPERIMENTAL ANIMAL; HEALTH CARE PLANNING; METHODOLOGY;

ANIMALIA;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ANIMALS, LABORATORY; ARRHYTHMIAS, CARDIAC; CARDIOTOXINS; DISEASE MODELS, ANIMAL; DRUG TOXICITY; EDUCATION; EUROPE; HEALTH PLANNING GUIDELINES; HUMANS;

EID: 77950939863     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-009-9045-3     Document Type: Conference Paper

References (124)

1. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug discovery, 3, 711-715.
2. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., & Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA, 287, 2215-2220.
3. Kennedy, T. (1997). Managing the drug discovery/development interface. Drug Discovery Today, 2(9), 436-444.
4. Redfern, W. S., Wakefield, I. D., Prior, H., Pollard, C. E., Hammond, T. G., & Valentin, J. P. (2002). Safety pharmacology- a progressive approach. Fundamental & Clinical Pharmacology, 16, 161-173.
5. Stephens, M. D. B. (2004). Stephens' detection of new adverse drug reactions. In J. Talbot & P. Waller (Eds.) (5th ed.). Malden, MA, USA: Wiley InterScience.
6. Fung, M., Thornton, A., Mybeck, K., Wu, J. H., Hornbuckle, K., & Muniz, E. (2001). Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceuticals markets-1960 to 1999. Drug Information Journal, 35, 293-317.
7. Car, B. (2006). Enabling technologies in reducing attrition due to safety failures. American Drug Discovery, 1, 31-34.
8. Krejsa, C. M., Horvath, D., Rogalski, S. L., et al. (2003). Predicting ADME properties and side effects: The bioprint approach. Current Opinion in Drug Discovery & Development, 6, 470-480.
9. Budnitz, D. S., Pollock, D. A., Weidenbach, K. N., Mendelsohn, A. B., Schroeder, T. J., & Annest, J. L. (2006). National surveillance of emergency department visits for outpatient adverse drug events. JAMA, 296, 1858-1866.
10. Lexchin, J. (2005). Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ, 172, 765-767.
11. Redfern, W. S., Carlsson, L., Davis, A. S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32-45.
12. EMEA. (1999). ICH topic S4 duration of chronic toxicity testing in animals rodent and non rodent toxicity testing. London: EMEA. http://www.emea.europa.eu/pdfs/human/ich/030095en. pdf. Accessed 09 Jan 2008.
13. EMEA. (2008). Guideline on repeated dose toxicity (draft). London: EMEA. http://www.emea.europa.eu/pdfs/human/swp/ 48831307en.pdf. Accessed 08 Aug 2008.
14. EMEA. (2001). ICH topic S7A safety pharmacology studies for human pharmaceuticals. London: EMEA. http://www.emea. europa.eu/pdfs/human/ich/ 053900en.pdf. Accessed 08 Aug 2007.
15. EMEA. (2005). ICH topic S7B the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by Human Pharmaceuticals. London: EMEA. http://www.emea.europa.eu/pdfs/human/ich/ 042302en.pdf. Accessed 08 Aug 2007.
16. Konorev, E. A., Vanamala, S., & Kalyanaraman, B. (2008). Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radical Biology and Medicine, 45, 1723-1728.
17. Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G., & Berghmans, S. (2008). Zebrafish: An emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology, 154, 1400-1413.
18. Robiolio, P. A., Rigolin, V. H., Wilson, J. S., et al. (1995). Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation, 92, 790-795.
19. Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992). Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Annals of Internal Medicine, 117, 50-52.
20. Roth, B. L. (2007). Drugs and valvular heart disease. New England Journal of Medicine, 356, 6-9.
21. Connolly, H. M., Crary, J. L., McGoon, M. D., et al. (1997). Valvular heart disease associated with fenfluramine-phentermine. New England Journal of Medicine, 337, 581-588.
22. Rothman, R. B., Baumann, M. H., Savage, J. E., et al. (2000). Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation, 102, 2836-2841.
23. Setola, V., Hufeisen, S. J., Grande-Allen, K. J., et al. (2003). 3, 4- methylenedioxymethamphetamine (MDMA, ''Ecstasy'') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Molecular Pharmacology, 63, 1223-1229.
24. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine, 356, 29-38.
25. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007). Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine, 356, 39-46.
26. Reiffel, J. A. (1996). Data-driven decisions: The importance of clinical trials in arrhythmia management. Journal of Cardiovascular Pharmacology and Therapeutics, 1, 79-88.
27. Hondeghem, L. M. (1994). Computer aided development of antiarrhythmic agents with class IIIa properties. Journal of Cardiovascular Electrophysiology, 5, 711-721.
28. Carmeliet, E., & Mubagwa, K. (1998). Antiarrhythmic drugs and cardiac ion channels: Mechanisms of action. Progress in Biophysics and Molecular Biology, 70, 1-72.
29. Whalley, D. W., Wendt, D. J., & Grant, A. O. (1995). Basic concepts in cellular cardiac electrophysiology: Part I: Ion channels, membrane currents, and the action potential. Pacing and Clinical Electrophysiology, 18, 1556-1574.
30. Lawrence, C. L., Pollard, C. E., Hammond, T. G., & Valentin, J. P. (2005). Nonclinical proarrhythmia models: Predicting Torsades de Pointes. Journal of Pharmacological and Toxicological Methods, 52, 46-59.
31. Carlsson, L., Abrahamsson, C., Andersson, B., Duker, G., & Schiller-Linhardt, G. (1993). Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovascular Research, 27, 2186-2193.
32. Detre, E., Thomsen, M. B., Beekman, J. D., Petersen, K. U., & Vos, M. A. (2005). Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: Confirming the relevance of shortterm variability of repolarisation in predicting drug-induced torsades de pointes. British Journal of Pharmacology, 145, 397-404.
33. Hondeghem, L. M. (2008). QT prolongation is an unreliable predictor of ventricular arrhythmia. Heart Rhythm, 5, 1210-1212.
34. Gintant, G. A., Su, Z., Martin, R. L., & Cox, B. F. (2006). Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicologic Pathology, 34, 81-90.
35. Antzelevitch, C., Shimizu, W., Yan, G. X., et al. (1999). The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. Journal of Cardiovascular Electrophysiology, 10, 1124-1152.
36. Shimizu, W., & Antzelevitch, C. (1999). Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. Journal of Electrocardiology, 32(Suppl), 177-184. (Pubitemid 30100125)
37. Gavillet, B., Rougier, J. S., Domenighetti, A. A., et al. (2006). Cardiac sodium channel Nav1.5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circulation Research, 99, 407-414.
38. Brendel, J., & Peukert, S. (2003). Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Current Medicinal Chemistry Cardiovascular & Hematological Agents, 1, 273-287.
39. Akiyama, T., Pawitan, Y., Greenberg, H., Kuo, C. S., & Reynolds- Haertle, R. A. (1991). Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Qwave acute myocardial infarction in the cardiac arrhythmia suppression trial. CAST investigators. American Journal of Cardiology, 68, 1551-1555.
40. Campbell, T. J. (1992). Subclassification of class I antiarrhythmic drugs: Enhanced relevance after CAST. Cardiovascular Drugs and Therapy, 6, 519-528.
41. Nagasawa, Y., Chen, J., & Hashimoto, K. (2005). Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: Comparison with other class III antiarrhythmic drugs. Journal of Pharmacological Science, 97, 393-399.
42. Vaughan Williams, E. M. (1959). A study of intracellular potentials and contractions in atria, including evidence for an after-potential. Journal of Physiology, 149, 78-92.
43. Ortega-Carnicer, J., Bertos-Polo, J., & Gutierrez-Tirado, C. (2001). Aborted sudden death, transient Brugada pattern, and wide QRS dysrhythmias after massive cocaine ingestion. Journal of Electrocardiology, 34, 345-349.
44. Ried, T., Rudy, B., Vega-Saenz, D. M., Lau, D., Ward, D. C., & Sen, K. (1993). Localization of a highly conserved human potassium channel gene (NGK2-KV4; KCNC1) to chromosome 11p15. Genomics, 15, 405-411.
45. Katchman, A. N., Koerner, J., Tosaka, T., Woosley, R. L., & Ebert, S. N. (2006). Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. Journal of Pharmacology and Experimental Therapeutics, 316, 1098-1106.
46. Sanguinetti, M. C., Curran, M. E., Spector, P. S., & Keating, M. T. (1996). Spectrum of HERG K Kκchannel dysfunction in an inherited cardiac arrhythmia. Proceedings of the National Academy of Sciences of the USA, 93, 2208-2212.
47. Fossa, A. A., Wisialowski, T., Wolfgang, E., et al. (2004). Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. European Journal of Pharmacology, 486(2), 209-221.
48. Saint, D. A. (2008). The cardiac persistent sodium current: An appealing therapeutic target? British Journal of Pharmacology, 153, 1133-1142.
49. Sasaki, K., Makita, N., Sunami, A., et al. (2004). Unexpected mexiletine responses of a mutant cardiac Na channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access. Molecular Pharmacology, 66, 330-336.
50. Nuss, H. B., & Marban, E. (1994). Electrophysiological properties of neonatal mouse cardiac myocytes in primary culture. Journal of Physiology, 479, 265-279.
51. Franco, D., Demolombe, S., Kupershmidt, S., et al. (2001). Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development. Cardiovascular Research, 52, 65-75.
52. Babij, P., Askew, G. R., Nieuwenhuijsen, B., et al. (1998). Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice. Circulation Research, 83, 668-678.
53. Bassani, R. A. (2006). Transient outward potassium current and Ca2+ homeostasis in the heart: Beyond the action potential. Brazilian Journal of Medical and Biological Research, 39, 393-403.
54. Carmeliet, E. (1993). K+ channels and control of ventricular repolarization in the heart. Fundamental & Clinical Pharmacology, 7, 19-28.
55. Ruppersberg, J. P., & Fakler, B. (1996). Complexity of the regulation of Kir2.1K+ channels. Neuropharmacology, 35, 887-893.
56. Heusch, G., Skyschally, A., Gres, P., van Caster, P., Schilawa, D., & Schulz, R. (2009). Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: Protection beyond heart rate reduction. European Heart Journal, 29(18), 2265-2275.
57. Rosen, M. R., Brink, P. R., Cohen, I. S., & Robinson, R. B. (2007). Biological pacemakers based on I(f). Medical & Biological Engineering & Computing, 45, 157-166.
58. Robinson, R. B., Brink, P. R., Cohen, I. S., & Rosen, M. R. (2006). I(f) and the biological pacemaker. Pharmacological Research, 53, 407-415.
59. Barbuti, A., Baruscotti, M., & DiFrancesco, D. (2007). The pacemaker current: From basics to the clinics. Journal of Cardiovascular Electrophysiology, 18, 342-347.
60. Jiang, M., Zhang, M., Tang, D. G., et al. (2004). KCNE2 protein is expressed in ventricles of different species, and changes in its expression contribute to electrical remodeling in diseased hearts. Circulation, 109, 1783-1788.
61. Cavero, I., & Crumb, W. (2005). ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: A critical analysis. Expert Opinion on Drug Safety, 4, 509-530.
62. Wehrens, X. H., Lehnart, S. E., Huang, F., et al. (2003). FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell, 113, 829-840.
63. Vest, J. A., Wehrens, X. H., Reiken, S. R., et al. (2005). Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation, 111, 2025-2032.
64. Koumi, S., & Wasserstrom, J. A. (1994). Acetylcholine-sensitive muscarinic K+ channels in mammalian ventricular myocytes. American Journal of Physiology, 266, H1812-H1821.
65. Liu, L., & Nattel, S. (1997). Differing sympathetic and vagal effects on atrial fibrillation in dogs: Role of refractoriness heterogeneity. American Journal of Physiology, 273, H805-H816.
66. Tucker, S. J., Gribble, F. M., Zhao, C., Trapp, S., & Ashcroft, F. M. (1997). Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. Nature, 387, 179-183.
67. Rodrigo, G. C., & Standen, N. B. (2005). ATP-sensitive potassium channels. Current Pharmaceutical Design, 11, 1915-1940.
68. Noma, A. (1983). ATP-regulated K+ channels in cardiac muscle. Nature, 305, 147-148.
69. Wilde, A. A., & Janse, M. J. (1994). Electrophysiological effects of ATP sensitive potassium channel modulation: Implications for arrhythmogenesis. Cardiovascular Research, 28, 16-24.
70. Murry, C. E., Jennings, R. B., & Reimer, K. A. (1986). Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation, 74, 1124-1136.
71. Gross, G. J., & Peart, J. N. (2003). KATP channels and myocardial preconditioning: An update. American Journal of Physiology- Heart and Circulatory Physiology, 285, H921-H930.
72. Le Brigand, L., Virsolvy, A., Manechez, D., et al. (1999). In vitro mechanism of action on insulin release of S-22068, a new putative antidiabetic compound. British Journal of Pharmacology, 128, 1021-1026.
73. Proks, P., Treinies, I., Mest, H. J., & Trapp, S. (2002). Inhibition of recombinant K(ATP) channels by the antidiabetic agents midaglizole, LY397364 and LY389382. European Journal of Pharmacology, 452, 11-19.
74. Mukai, E., Ishida, H., Horie, M., Noma, A., Seino, Y., & Takano, M. (1998). The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Biochemical and Biophysical Research Communications, 251(2), 477-481.
75. Zunkler, B. J., Kuhne, S., Rustenbeck, I., Ott, T., & Hildebrandt, A. G. (2000). Disopyramide block of K(ATP) channels is mediated by the pore-forming subunit. Life Sciences, 66, L-52.
76. Gribble, F. M., Davis, T. M., Higham, C. E., Clark, A., & Ashcroft, F. M. (2000). The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. British Journal of Pharmacology, 131, 756-760.
77. Zunkler, B. J., & Wos, M. (2003). Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K(+) channels. Life Sciences, 73, 429-435.
78. Zunkler, B. J., Claassen, S., Wos-Maganga, M., Rustenbeck, I., & Holzgrabe, U. (2006). Effects of fluoroquinolones on HERG channels and on pancreatic beta-cell ATP-sensitive K+ channels. Toxicology, 228, 239-248.
79. Saraya, A., Yokokura, M., Gonoi, T., & Seino, S. (2004). Effects of fluoroquinolones on insulin secretion and beta-cell ATPsensitive K+ channels. European Journal of Pharmacology, 497, 111-117.
80. Kikuta, J., Ishii, M., Kishimoto, K., & Kurachi, Y. (2006). Carvedilol blocks cardiac KATP and KG but not IK1 channels by acting at the bundle-crossing regions. European Journal of Pharmacology, 529, 47-54.
81. Rang, H. P., Dale, M. M., Ritter, J. M., Flower, R. J. (2007). Pharmacology. Churchill Livingstone Elsevier (6th ed.).
82. Bernstein, D., Fajardo, G., Zhao, M., et al. (2005). Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. American Journal of Physiology-Heart and Circulatory Physiology, 289, H2441-H2449.
83. Nuttall, S. L., Langford, N. J., & Kendall, M. J. (2000). Betablockers in heart failure. 1. Clinical evidence. Journal of Clinical Pharmacy & Therapeutics, 25, 395-398.
84. Zhu, W. Z., Zheng, M., Koch, W. J., Lefkowitz, R. J., Kobilka, B. K., & Xiao, R. P. (2001). Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proceedings of the National Academy of Sciences of the USA, 98, 1607-1612.
85. Rona, G. (1985). Catecholamine cardiotoxicity. Journal of Molecular and Cellular Cardiology, 17, 291-306.
86. Harvey, R. D., & Belevych, A. E. (2003). Muscarinic regulation of cardiac ion channels. British Journal of Pharmacology, 139, 1074-1084.
87. Kurachi, Y. (1995). G protein regulation of cardiac muscarinic potassium channel. American Journal of Physiology, 269, C821-C830.
88. James, A. F., & Hancox, J. C. (2007). More types than one: Multiple muscarinic receptor coupled K+ currents undergo remodelling in an experimental model of atrial fibrillation. British Journal of Pharmacology, 152, 981-983.
89. Shields, J. A. (2008). Heart block and prolonged Q-Tc interval following muscle relaxant reversal: A case report. AANA Journal, 76, 41-45.
90. Bunemann, M., Lee, K. B., Pals-Rylaarsdam, R., Roseberry, A. G., & Hosey, M. M. (1999). Desensitization of G-protein-coupled receptors in the cardiovascular system. Annual Review of Physiology, 61, 169-192.
91. Cingolani, H. E., & Ennis, I. L. (2007). Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation, 115, 1090-1100.
92. Fliegel, L. (2009). Regulation of the Na(+)/H(+) exchanger in the healthy and diseased myocardium. Expert Opinion on Therapeutic Targets, 13, 55-68.
93. Karmazyn, M., Sawyer, M., & Fliegel, L. (2005). The Na(+)/ H(+) exchanger: A target for cardiac therapeutic intervention. Current Drug Targets Cardiovascular & Hematological Disorders, 5, 323-335.
94. Nakamura, T. Y., Iwata, Y., Arai, Y., Komamura, K., & Wakabayashi, S. (2008). Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circulation Research, 103, 891-899.
95. Takemasa, H., Nagatomo, T., Abe, H., et al. (2008). Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. British Journal of Pharmacology, 153, 439-447.
96. van der Heyden, M. A., Smits, M. E., & Vos, M. A. (2008). Drugs and trafficking of ion channels: A new pro-arrhythmic threat on the horizon? British Journal of Pharmacology, 153, 406-409.
97. Dennis, A., Wang, L., Wan, X., & Ficker, E. (2007). hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochemical Society Transactions, 35, 1060-1063.
98. Guo, J., Massaeli, H., Li, W., et al. (2007). Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics, 321, 911-920.
99. Rajamani, S., Eckhardt, L. L., Valdivia, C. R., et al. (2006). Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. British Journal of Pharmacology, 149, 481-489.
100. Hoffmann, P., & Warner, B. (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. Journal of Pharmacological and Toxicological Methods, 53, 87-105.
101. Friedrichs, G. S., Patmore, L., & Bass, A. (2005). Non-clinical evaluation of ventricular repolarization (ICH S7B): Results of an interim survey of international pharmaceutical companies. Journal of Pharmacological and Toxicological Methods, 52, 6-11.
102. Lindgren, S., Bass, A. S., Briscoe, R., et al. (2008). Benchmarking safety pharmacology regulatory packages and best practice. Journal of Pharmacological and Toxicological Methods, 58, 99-109.
103. Gavaghan, C. L., Arnby, C. H., Blomberg, N., Strandlund, G., & Boyer, S. (2007). Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. Journal of Computer-Aided Molecular Design, 21, 189-206.
104. Thai, K. M., & Ecker, G. F. (2007). Predictive models for HERG channel blockers: Ligand-based and structure-based approaches. Current Medicinal Chemistry, 14, 3003-3026.
105. Courtemanche, M., Ramirez, R. J., & Nattel, S. (1999). Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insights from a mathematical model. Cardiovascular Research, 42, 477-489.
106. Diaz, G. J., Daniell, K., Leitza, S. T., et al. (2004). The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. Journal of Pharmacological and Toxicological Methods, 50, 187-199.
107. Rezazadeh, S., Hesketh, J. C., & Fedida, D. (2004). Rb+ flux through hERG channels affects the potency of channel blocking drugs: Correlation with data obtained using a high-throughput Rb+ efflux assay. Journal of Biomolecular Screening, 9, 588-597.
108. Liu, C. J., Priest, B. T., Bugianesi, R. M., et al. (2006). A highcapacity membrane potential FRET-based assay for NaV1.8 channels. Assay Drug Development Technologies, 4, 37-48.
109. Bianchi, L., Wible, B., Arcangeli, A., et al. (1998). Herg encodes a K+ current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells? Cancer Research, 58, 815-822.
110. Finkel, A., Wittel, A., Yang, N., Handran, S., Hughes, J., & Costantin, J. (2006). Population patch clamp improves data consistency and success rates in the measurement of ionic currents. Journal of Biomolecular Screening, 11, 488-496.
111. Halbach, M., Egert, U., Hescheler, J., & Banach, K. (2003). Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures 2. Cellular Physiology and Biochemistry, 13, 271-284.
112. Meyer, T., Sartipy, P., Blind, F., Leisgen, C., & Guenther, E. (2007). New cell models and assays in cardiac safety profiling. Expert Opinion on Drug Metabolism & Toxicology, 3, 507-517.
113. Pillekamp, F., Halbach, M., Reppel, M., et al. (2007). Neonatal murine heart slices. A robust model to study ventricular isometric contractions. Cellular Physiology and Biochemistry, 20, 837-846.
114. Halbach, M., Pillekamp, F., Brockmeier, K., Hescheler, J., Muller-Ehmsen, J., & Reppel, M. (2006). Ventricular slices of adult mouse hearts-a new multicellular in vitro model for electrophysiological studies. Cellular Physiology and Biochemistry, 18, 1-8.
115. Yan, G. X., & Antzelevitch, C. (1998). Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation, 98, 1928-1936. (Pubitemid 28509291)
116. Hondeghem, L. M., Carlsson, L., & Duker, G. (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation, 103, 2004-2013.
117. Carlsson, L., Almgren, O., & Duker, G. (1990). QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. Journal of Cardiovascular Pharmacology, 16, 276-285.
118. Vos, M. A., Verduyn, S. C., Gorgels, A. P., Lipcsei, G. C., & Wellens, H. J. (1995). Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation, 91, 864-872.
119. Carlsson, L. (2006). In vitro and in vivo models for testing arrhythmogenesis in drugs. Journal of Internal Medicine, 259, 70-80.
120. Wu, L., Shryock, J. C., Song, Y., & Belardinelli, L. (2006). An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. Journal of Pharmacology and Experimental Therapeutics, 316, 718-726.
121. Fossa, A. A., Depasquale, M. J., Raunig, D. L., Avery, M. J., & Leishman, D. J. (2002). The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. Journal of Pharmacology and Experimental Therapeutics, 302, 828-833.
122. Svernhage, E., Houltz, B., Blomström, P., et al. (1998). Early electrocardiographic signs of drug-induced torsades de pointes. Annals of Noninvasive Electrocardiology, 3, 252-260.
123. Atiga, W. L., Calkins, H., Lawrence, J. H., Tomaselli, G. F., Smith, J. M., & Berger, R. D. (1998). Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. Journal of Cardiovascular Electrophysiology, 9, 899-908.
124. Berger,R.D.,Kasper,E.K., Baughman,K.L.,Marban,E., Calkins, H., & Tomaselli, G. F. (1997). Beat-to-beatQT interval variability: Novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation, 96, 1557-1565.